# Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

> **NCT00882102** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 43 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Gemtuzumab ozogamicin

## Key facts

- **NCT ID:** NCT00882102
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2013-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00882102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00882102, "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00882102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*